Doxorubicin+cisplatin+ifosfamide

PreclinicalSmall molecule

Doxorubicin+cisplatin+ifosfamide is one of 23 small molecule programs targeting Bone Sarcoma. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Bone SarcomaActive, not recruiting

Bone SarcomaPreclinical

Active, not recruiting

Competition

Competitive Landscape

26 competitors in Bone Sarcoma

#DrugCompanyPhaseTrials

Afinitor

DTIC-Dome

2 3

Trexall

Alnylam Pharmaceuticals

Phase 2

2 4

Ridaforolimus

Votrient

1 6

Stivarga

Bayer

Phase 2

1 7

Adriamycin

Pfizer

Phase 2

1 8

Ellence

Pfizer

Phase 2

1 9

Sutent

Pfizer

Phase 2

1 10

Opdivo

Bristol-Myers Squibb

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Bone Sarcoma1 trial

European Study in Bone Sarcoma Patients Over 40 Years

Completed·IItalian Sarcoma Group··NCT02986503·100 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Doxorubicin+cisplatin+ifosfamide. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Doxorubicin+cisplatin+ifosfamide compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Doxorubicin+cisplatin+ifosfamide. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Italian Sarcoma Group company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: IItalian Sarcoma Group

Doxorubicin+cisplatin+ifosfamide

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Bone Sarcoma1 trial

References

Drug Info

Quick Facts

Related News